- Home
- CABA vs GIW Comparison
CABA vs GIW Comparison
Compare CABA & GIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CABA | GIW |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.9M | 370.6M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CABA | GIW |
|---|---|---|
| Price | $2.59 | $10.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 119.9K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $9.87 |
| 52 Week High | $4.23 | $10.18 |
Technical Indicators
Market Signals| Indicator | CABA | GIW |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 63.15 |
| Support Level | $2.02 | $10.08 |
| Resistance Level | $3.41 | N/A |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 7.48 | 50.00 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About GIW GigCapital8 Corp. Class A Ordinary Shares
GigCapital8 Corp is a blank check company.